- Home
- SNY vs ITUB Comparison
SNY vs ITUB Comparison
Compare SNY & ITUB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNY | ITUB |
|---|---|---|
| Founded | 1994 | 1924 |
| Country | France | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4B | 81.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SNY | ITUB |
|---|---|---|
| Price | $46.56 | $7.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $61.50 | $7.77 |
| AVG Volume (30 Days) | 2.7M | ★ 14.9M |
| Earning Date | 01-29-2026 | 02-04-2026 |
| Dividend Yield | 3.43% | ★ 9.81% |
| EPS Growth | ★ 105.93 | 13.27 |
| EPS | ★ 8.67 | 0.74 |
| Revenue | ★ $53,890,648,839.00 | $25,400,232,630.00 |
| Revenue This Year | $1.73 | $39.16 |
| Revenue Next Year | $6.49 | $7.43 |
| P/E Ratio | $10.59 | ★ $9.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $44.62 | $4.63 |
| 52 Week High | $60.12 | $7.89 |
Technical Indicators
Market Signals| Indicator | SNY | ITUB |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 50.87 |
| Support Level | $46.68 | $7.29 |
| Resistance Level | $48.17 | $7.52 |
| Average True Range (ATR) | 0.65 | 0.10 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 4.21 | 74.18 |
Price Performance
Historical ComparisonAbout SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About ITUB Itau Unibanco Banco Holding SA (Each repstg 500 Preferred shares)
Itaú Unibanco is the largest privately held bank in Brazil, the result of the 2008 merger between Banco Itaú and Unibanco. In addition to Brazil, the bank has significant operations in Chile, Colombia, Argentina, Uruguay, and Paraguay. Itaú's commercial and consumer loans account for 35% and 43% of the bank's total loans, respectively, while foreign loans account for 22% of its portfolio. The bank also operates the fifth-largest insurer in Brazil and is the second-largest asset manager in the country, giving it broad reach over the Brazilian financial system.